A Phase 3 Study to Evaluate the Efficacy and Safety of CLS006 Versus Vehicle in Subjects 2 Years of Age or Older With Cutaneous Common Warts

ClinicalTrials.gov ID: NCT02971891

Public ClinicalTrials.gov record NCT02971891. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Jul 23, 2026, 1:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Randomized, Double-Blind, Vehicle-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of CLS006 Versus Vehicle in Subjects 2 Years of Age or Older With Cutaneous Common Warts

Study identification

NCT ID: NCT02971891
Recruitment status: Completed
Study type: Interventional
Phase: Phase 3
Lead sponsor: Maruho Co., Ltd.; Industry
Enrollment: 484 participants

Conditions and interventions

Conditions

Cutaneous Common Warts

Interventions

CLS006 (Furosemide) Topical Gel Drug
Vehicle Topical Gel Drug

Drug

Eligibility (public fields only)

Age range: 2 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Dec 31, 2016
Primary completion: Apr 15, 2018
Completion: Jul 9, 2018
Last update posted: Sep 13, 2023

2017 – 2018

United States locations

U.S. sites: 30
U.S. states: 18
U.S. cities: 29

Facility	City	State	ZIP	Site status
Not listed	Mobile	Alabama	36608	—
Not listed	Glendale	Arizona	85308	—
Not listed	Los Angeles	California	90045	—
Not listed	Santa Monica	California	90404	—
Not listed	Santa Rosa	California	95403	—
Not listed	Denver	Colorado	80220	—
Not listed	Miami	Florida	33137	—
Not listed	North Miami Beach	Florida	33162	—
Not listed	Ormond Beach	Florida	32174	—
Not listed	Tampa	Florida	33624	—
Not listed	Plainfield	Indiana	46168	—
Not listed	Lake Charles	Louisiana	70605	—
Not listed	Monroe	Louisiana	71203	—
Not listed	Hunt Valley	Maryland	21030	—
Not listed	Beverly	Massachusetts	01915	—
Not listed	Fort Gratiot	Michigan	480059	—
Not listed	Omaha	Nebraska	68144	—
Not listed	Portsmouth	New Hampshire	03801	—
Not listed	New York	New York	10022	—
Not listed	High Point	North Carolina	27262	—
Not listed	Wilmington	North Carolina	28405	—
Not listed	Fort Washington	Pennsylvania	19034	—
Not listed	Hazleton	Pennsylvania	18201	—
Not listed	Austin	Texas	78759	—
Not listed	College Station	Texas	77845	—
Not listed	Katy	Texas	77494	—
Not listed	San Antonio	Texas	78213	—
Not listed	San Antonio	Texas	78229	—
Not listed	Salt Lake City	Utah	84117	—
Not listed	Lynchburg	Virginia	24501	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02971891, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Sep 13, 2023 · Synced Jul 23, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02971891 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →